COG-TB: Cognitive Fusion guided prostate targeted Biopsy
ProcedureCognitive Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
NCT Number: NCT06504017
To compare the positive detection rates of COG-TB vs FUS-TB for prostate cancer with PI-RADS 4 small lesions.
Trial opening soon.
Get Notified18 year–80 year
Male
Interventional
Not applicable
Prostate cancer (PCA) is the most frequent malignancy in male urogenital system. According to the World Health Organization's 2020 GLOBOCAN statistics, there are approximately 1.4 million new cases and 375,000 deaths worldwide. PCa is the second most common tumor in male patients after lung cancer and ranks fifth among cancer causes of death.
Currently, prostate specific antigen ( PSA ), digital rectal examination (DRE), multi-parametric magnetic resonance imaging (mpMRI), prostate specific membrane antigen positron emission Tomography/computed tomography (PSMA PET/CT) and other detection methods have played an important role in the diagnosis of PCa, but the gold standard for confirming PCa is the histopathological examination of prostate biopsy. Performing mpMRI before biopsy can help detect and locate prostate cancer with ISUP grade ≥2. Studies have shown that the prostate imaging reporting and data system (PI-RADS) may help improve the detection of clinically significant cancers. Biopsy should be considered when PI-RADS score 4 or 5.
This clinical study intends to use the mpMRI-TRUS image fusion ultrasound system to assist in guiding FUS-TB, comparing to COG-TB to evaluate the application value of mpMR-TRUS image fusion in the detection of PCa in prostate biopsy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Cognitive Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
MRI-TRUS Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
Time frame: 1 week (after pathology)
detection rate of any prostate cancer
Time frame: 1 week (after pathology)
detection rate for PI-RADS 4 small lesion (<5mm) under MRI-TRUS fusion
Contact information is provided by the study sponsor or research team.
Shangqian Wang, PhD
CONTACT
Xu Wang
CONTACT
The First Affiliated Hospital with Nanjing Medical University
Other
FUS-TB VS COG-TB in Prostate Cancer With PI-RADS 4 Small Lesions - a Predictive, Multi-center, Exploring Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07574541
Adenocarcinoma, Carcinoma
Bethesda, Maryland, United States
View Trial DetailsNCT07686380
Genital Diseases, Genital Diseases, Male
Bethesda, Maryland, United States
View Trial DetailsNCT07667400
Adenocarcinoma, Adenoid Cystic Carcinoma
Bethesda, Maryland, United States
View Trial DetailsNCT07737925
Genital Diseases, Genital Diseases, Male
View Trial Details